Crizotinib 250mg Capsules

Crizotinib 250mg Capsules is a pioneering, small-molecule tyrosine kinase inhibitor (TKI) that revolutionized the treatment of non-small cell lung cancer (NSCLC) by ushering in the era of precision medicine. It acts as a potent inhibitor of the Anaplastic Lymphoma Kinase (ALK), ROS1, and c-MET receptor tyrosine kinases. In patients whose tumors harbor specific genetic rearrangements (like the EML4-ALK fusion), these kinases are permanently “switched on,” driving uncontrolled cell growth and survival. Crizotinib 250mg Capsules works by competitively binding to the ATP-binding pocket of these abnormal kinases, effectively shutting down the phosphorylation process. This blockade halts downstream signaling pathways (such as STAT3, PI3K/Akt, and MAPK), leading to the arrest of tumor proliferation and the induction of apoptosis (cell death). Discover how this professional pharmaceutical intervention provides the ultimate clinical strategy for biomarker-driven lung cancer therapy, offering a targeted lifeline to patients with specific genetic profiles.

The 250mg capsule is the standard dosage unit for the recommended starting dose of 250mg twice daily. This high-strength formulation simplifies the regimen, allowing patients to take one capsule in the morning and one in the evening. Consistent dosing at this level is crucial to maintain steady-state plasma concentrations sufficient to inhibit the target kinases continuously. The capsule formulation also allows for dose reduction strategies (to 200mg or separate 250mg once daily) if adverse effects occur.

Indications / Uses of Crizotinib 250mg Capsules

Crizotinib 250mg Capsules is commonly prescribed for the specialized management of the following biologically defined malignancies:

• ALK-Positive NSCLC: It is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
• ROS1-Positive NSCLC: The medication is indicated for the treatment of patients with metastatic NSCLC whose tumors are ROS1-positive.
• ALCL ( Pediatric & Young Adult): It is indicated for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.
• IMT (Pediatric & Adult): It is indicated for the treatment of adult and pediatric patients with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive.

Key Features

• Multi-Kinase Inhibition: The primary feature of Crizotinib 250mg Capsules is its ability to target three distinct oncogenic drivers (ALK, ROS1, and MET), making it a versatile tool in precision oncology.
• Biomarker-Driven Efficacy: It demonstrates exceptionally high response rates (often >60-70%) specifically in patients with the correct genetic match, far superior to standard chemotherapy in this population.
• Oral Administration: The twice-daily oral regimen offers a convenient, non-invasive alternative to intravenous therapies.
• Rapid Tumor Shrinkage: Patients often experience rapid symptomatic improvement, sometimes within weeks of starting therapy.
• Standard of Care: It established the paradigm for treating ALK+ lung cancer and remains a critical option in the treatment landscape.

Storage for Crizotinib 250mg Capsules

To preserve the pharmacological stability and ultimate potency of the active ingredients, Crizotinib 250mg Capsules should be stored at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). Excursions are permitted between 15°C and 30°C (59°F to 86°F). It is vital to keep the capsules in their original bottle to protect them from moisture and light. Do not remove the capsules from the bottle until just before dosing. For maximum safety, always store Crizotinib 250mg Capsules in a secure, high location that is strictly out of the reach and sight of children and pets.

Important Note on Crizotinib 250mg Capsules

The administration of Crizotinib 250mg Capsules is associated with unique visual side effects. Vision Disorders (such as trails of light, flashes, or blurred vision) occur in a majority of patients, typically starting within two weeks of treatment. These are usually mild but patients should be cautioned about driving at night or operating machinery.

Hepatotoxicity (liver damage) can occur; potentially fatal drug-induced liver injury has been reported. Liver function tests (transaminases and bilirubin) must be monitored every 2 weeks for the first 2 months. QT Interval Prolongation and Bradycardia (slow heart rate) are significant cardiac risks; ECGs and electrolyte monitoring are required periodically.

Interstitial Lung Disease (ILD)/Pneumonitis can be severe or life-threatening; patients with new or worsening pulmonary symptoms must stop the drug immediately for evaluation. Crizotinib 250mg Capsules can cause fetal harm (Pregnancy Category D); effective contraception is mandatory for both men and women during treatment and for at least 3 months after the final dose. By strictly following these professional guidelines and monitoring protocols, healthcare providers can safely maximize the targeted benefits of Crizotinib 250mg Capsules.